Annotation Detail

Information
Associated Genes
KRAS
Associated Variants
KRAS p.Gly12Asp (p.G12D) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 )
KRAS p.Gly12Asp (p.G12D) ( ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 )
Associated Disease
pancreatic carcinoma
Source Database
CIViC Evidence
Description
Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss and a KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/937
Gene URL
https://civic.genome.wustl.edu/links/genes/30
Variant URL
https://civic.genome.wustl.edu/links/variants/79
Rating
2
Evidence Type
Predictive
Disease
Pancreatic Carcinoma
Evidence Direction
Supports
Drug
Akt Inhibitor MK2206
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
22025163
Drugs
Drug NameSensitivitySupported
Akt Inhibitor MK2206Sensitivitytrue